Then they found that miR-141 level changes were similar with changes observed by PSA, LDH and CTC and to the clinical assessments of the patients, suggests miR-141 can be used as a marker for therapeutic response in PCa patients. This evidence concerns the gene KLK3 and posterior cortical atrophy.